A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Single Ascending and Multiple Oral Doses of MB-110 and to Evaluate the Antiviral Activity in Hepatitis C Virus Infected Patients

Trial Profile

A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Single Ascending and Multiple Oral Doses of MB-110 and to Evaluate the Antiviral Activity in Hepatitis C Virus Infected Patients

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs MB 110 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
  • Sponsors MICROBIO Group
  • Most Recent Events

    • 04 Apr 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 04 Apr 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
    • 04 Apr 2017 Planned initiation date changed from 1 Jan 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top